1490 O’Brien Drive
19 articles with TeneoBio, Inc.
Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, announced today the publication of its bispecific human heavy chain only antibody (TNB-409) with selective IL-2βγ receptor heterodimeric agonist activity in Scientific Reports ( www.nature.com/articles/s41598-021-90096-8 ).
Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, reported the Phase I clinical entry and the dosing of patients with the bispecific JNJ-75348780 in a Phase I study (https://clinicaltrials.gov/ct2/show/NCT04540796), which is sponsored by Janssen Research & Development, LLC (Janssen)
Teneobio Announces FDA Clearance of IND for TNB-585 and Initiation of Phase I Clinical Studies for Metastatic Castrate Resistant Prostate Cancer
Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific T-cell engaging antibody for the treatment of metastatic castrate resistant prostate cancer (mCRPC) was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on January 23, 2021. Therapeutic options for mCRPC are limited, and those that are available imp
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four options to commercial licenses for Teneobio human heavy chain only domain antibodies, UniDabs®, to develop novel CAR T therapies.
Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology
Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today announced the presentation of interim clinical data from its Phase 1 trial evaluating TNB-383B in relapsed/refractory multiple myeloma (R/R MM) at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually Dec. 5-8, 2020. TNB-383B is a fully human bispecifi
Teneobio, Inc. and its affiliate TeneoFour, Inc. announced a Nature Metabolism publication of a proof of concept study by the Chini Laboratory describing the rejuvenation of energy metabolism in aged mice undergoing therapy with Teneobio’s CD38 blocker.
Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies
Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced that their investigational new drug application for TNB-486, a bispecific T-cell engaging antibody for the treatment of B-Cell Non-Hodgkin’s lymphoma was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration on September 30, 2020.
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9 therapeutics company, to use Teneobio’s Heavy Chain Antibodies (UniAbs ® ) for Intellia’s next generation engineered cell therapies. In addition, Teneobio will use its proprietary platforms to discover novel UniAbs ® against targets which can be used in engineered cell therapies for various life-threateni
Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies
Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma
Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that it has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology
Selexis SA and Teneobio, Inc. announced that they have signed three commercial license agreements for the development of Teneobio’s Human Heavy-Chain Antibodies, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer.
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
AbbVie is taking a $90 million plunge into B-cell maturation antigen (BCMA)-targeting immunotherapeutics against multiple myeloma in a collaborative deal with Menlo Park, Calif.-based Teneobio, Inc.
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
Data showed results from the application of TeneoBio’s suite of technologies in the generation of the lead therapeutic candidate.
TeneoBio, Inc. And Poseida Therapeutics Announce License Agreement For The Use Of Unidab In CAR T-Cell Therapy
TeneoBio, Inc.’s Next Generation T Cell Redirection Antibody Platform For Cancer Biotherapeutics Offers Prospects Of Reducing Cytokine Release